FY2026 Earnings Estimate for TSE:MDP Issued By Stifel Canada

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities research analysts at Stifel Canada issued their FY2026 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a research note issued on Thursday, February 6th. Stifel Canada analyst J. Keywood expects that the company will post earnings of $0.10 per share for the year. Stifel Canada currently has a "Hold" rating on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.

Other equities analysts have also issued reports about the company. Stifel Nicolaus lowered Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and decreased their target price for the stock from C$6.00 to C$3.45 in a research note on Friday, February 7th. Leede Financial upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 target price on the stock in a research note on Wednesday, January 8th. Ventum Financial upped their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a "buy" rating in a report on Thursday, January 30th. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Medexus Pharmaceuticals has an average rating of "Buy" and an average target price of C$5.49.

Medexus Pharmaceuticals Price Performance

TSE MDP traded up C$0.02 during trading on Monday, reaching C$3.14. The company's stock had a trading volume of 32,472 shares, compared to its average volume of 184,147. The stock has a market capitalization of C$70.30 million, a PE ratio of 15.02 and a beta of 1.96. The firm has a fifty day moving average of C$3.56 and a 200 day moving average of C$2.85. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.